Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
CONCLUSION: In hereditary OC syndromes, mutations in DNA repair pathways form the clinical basis for the use of PARP inhibitors and an immune checkpoint inhibitor as novel targeted therapies.
PMID: 30228165 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Burgess BT, Kolesar JM Tags: Am J Health Syst Pharm Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Drugs & Pharmacology | Faconi Anemia | Gastroschisis Repair | Genetics | HNPCC | Lynch Syndrome | Ovarian Cancer | Ovaries